ConductScience.org, home

Paper41769697

Remdesivir in COVID-19: pros and cons.

Rouhana El Feghali Y and 3 others. Front Pharmacol, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Remdesivir in COVID-19: pros and cons. Papers, record 41769697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41769697

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Remdesivir in COVID-19: pros and cons.
PubMed
Journal
Front Pharmacol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rouhana El Feghali YYara
2Rabih LLayan
3Abdul Khalek JJad
4Arabi MMariam

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References86

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133128197Emerging treatment strategies for COVID-19 infection.Clin Exp Med2021https://conductscience.org/library/papers/33128197PubMed
233782830Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.Clin Pharmacokinet2021https://conductscience.org/library/papers/33782830PubMed
338023628Efficacy and Safety of Remdesivir in Hospitalized Pediatric COVID-19: A Retrospective Case-Controlled Study.Ther Clin Risk Manag2023https://conductscience.org/library/papers/38023628PubMed
436603741Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.Pulm Pharmacol Ther2023https://conductscience.org/library/papers/36603741PubMed
541160817Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026.N Engl J Med2025https://conductscience.org/library/papers/41160817PubMed
632468196Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.Drug Saf2020https://conductscience.org/library/papers/32468196PubMed
735634324Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.Front Immunol2022https://conductscience.org/library/papers/35634324PubMed
833856918COVID-19 and Cardiovascular Disease: From Bench to Bedside.Circ Res2021https://conductscience.org/library/papers/33856918PubMed
932015507A pneumonia outbreak associated with a new coronavirus of probable bat origin.Nature2020https://conductscience.org/library/papers/32015507PubMed
1033674391COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.J Pharmacol Exp Ther2021https://conductscience.org/library/papers/33674391PubMed
1133264556Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.N Engl J Med2021https://conductscience.org/library/papers/33264556PubMed
1232821939Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.JAMA2020https://conductscience.org/library/papers/32821939PubMed
1336149807Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program.J Clin Pharmacol2023https://conductscience.org/library/papers/36149807PubMed
1434358081ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/34358081PubMed
1533802215Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters.Pharmaceutics2021https://conductscience.org/library/papers/33802215PubMed
1633795039COVID-19 in Adults With Congenital Heart Disease.J Am Coll Cardiol2021https://conductscience.org/library/papers/33795039PubMed
1736036936Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial.JAMA Netw Open2022https://conductscience.org/library/papers/36036936PubMed
1836052127Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment.Front Pharmacol2022https://conductscience.org/library/papers/36052127PubMed
1933400058Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.AAPS J2021https://conductscience.org/library/papers/33400058PubMed
2028659436Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.Sci Transl Med2017https://conductscience.org/library/papers/28659436PubMed

See all 86 referencesDownload CSV of references

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CES11066PubTator's text mininghttps://conductscience.org/library/genes/1066NCBI Gene
CTSA5476PubTator's text mininghttps://conductscience.org/library/genes/5476NCBI Gene
CYP3A41576PubTator's text mininghttps://conductscience.org/library/genes/1576NCBI Gene
SLC47A155244PubTator's text mininghttps://conductscience.org/library/genes/55244NCBI Gene
SLCO1B110599PubTator's text mininghttps://conductscience.org/library/genes/10599NCBI Gene
SLCO1B328234PubTator's text mininghttps://conductscience.org/library/genes/28234NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41769697

GET https://conductscience.org/api/papers/v1/41769697/references?page=2